Development of extracellular signal-regulated kinase inhibitors.
Activation of the extracellular signal-regulated kinase (ERK) signaling pathway has been implicated in mediating a diverse array of cellular functions including cell differentiation, proliferation, and inflammatory responses. In this review, we will discuss approaches to identify inhibitors of ERK proteins through targeting ATP-dependent and ATP-independent mechanisms. Given the diversity of ERK substrates and the importance of ERK signaling in normal cell functions, emphasis will be placed on the methods for identifying small molecular weight compounds that are substrate selective through ATP-independent interactions and potentially relevant to inflammatory processes. The approach for selective targeting of ERK substrates takes advantage of the basic understanding of unique ERK docking domains that are thought to interact with specific amino acid sequences on substrate proteins. Computer aided drug design (CADD) can facilitate the high throughput screening of millions of compounds with the potential for selective interactions with ERK docking domains and disruption of substrate interactions. As such, the CADD approach significantly reduces the number of compounds that will be evaluated in subsequent biological assays and greatly increases the hit rate of biologically active compounds. The potentially active compounds are evaluated for ERK protein binding using spectroscopic and structural biology methods. Compounds that show ERK interactions are then tested for their ability to inhibit substrate interactions and phosphorylation as well as ERK-dependent functions in whole organism or cell-based assays. Finally, the relevance of substrate-selective ERK inhibitors in the context of inflammatory disease will be discussed.
Burkhard
Kimberly
K
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.
Smith
Sarice
S
Deshmukh
Rahul
R
MacKerell
Alexander D
AD
Shapiro
Paul
P
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D015195:Drug Design; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors*; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D047428:Protein Kinase Inhibitors; D000255:Adenosine Triphosphate; D048049:Extracellular Signal-Regulated MAP Kinases; D020928:Mitogen-Activated Protein Kinases
Nature. 2002 Jun 27;417(6892):949-54
12068308
Biophys Chem. 2001 Nov 28;93(2-3):215-30
11804727
Mol Microbiol. 1998 Jun;28(6):1335-43
9680221
EMBO Rep. 2006 Aug;7(8):782-6
16880823
Curr Top Med Chem. 2002 Sep;2(9):1011-20
12171568
Science. 1999 Nov 12;286(5443):1374-7
10558995
Curr Drug Targets Infect Disord. 2002 Sep;2(3):217-34
12462126
J Chem Inf Model. 2007 Nov-Dec;47(6):2303-15
17900106
Nat Biotechnol. 2005 Mar;23(3):329-36
15711537
Mol Cell. 2004 Apr 9;14(1):43-55
15068802
Curr Opin Chem Biol. 2001 Dec;5(6):654-9
11738175
J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
16002463
J Biol Chem. 2003 Aug 8;278(32):29901-12
12754209
Cell. 1997 Sep 5;90(5):859-69
9298898
Genes Dev. 1994 Jan;8(2):147-59
8299935
J Med Chem. 2007 Mar 22;50(6):1280-7
17300186
J Comput Aided Mol Des. 2000 Mar;14(3):251-64
10756480
Proteins. 2008 Dec;73(4):795-801
18767165
Biochem J. 2003 Apr 1;371(Pt 1):199-204
12534346
J Biol Chem. 1999 Nov 26;274(48):34029-35
10567369
Mol Cell Biol. 1998 Feb;18(2):710-20
9447967
Endocr Rev. 2001 Apr;22(2):153-83
11294822
J Med Chem. 2007 Feb 8;50(3):409-24
17266192
J Biol Chem. 1999 Jul 30;274(31):21900-7
10419510
Ann Rheum Dis. 2008 Jul;67(7):909-16
17827184
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):316-23
16324895
J Biol Chem. 1995 Jul 14;270(28):16483-6
7622446
Curr Opin Drug Discov Devel. 2003 Sep;6(5):760-5
14579525
Anticancer Res. 2005 May-Jun;25(3A):1483-9
16033049
Curr Opin Struct Biol. 2003 Feb;13(1):115-21
12581668
Oncologist. 2005 Sep;10(8):565-78
16177281
Biochemistry. 2004 Sep 21;43(37):11658-71
15362850
J Cell Commun Signal. 2008 Dec;2(3-4):81-92
19105050
Lancet. 2008 Sep 20;372(9643):1073-87
18805336
Semin Oncol. 2006 Aug;33(4):369-85
16890793
J Biol Chem. 1995 Jun 23;270(25):14843-6
7797459
Expert Rev Mol Med. 2002 Apr 25;4(8):1-18
14987392
Nucleic Acids Res. 2002 Jan 1;30(1):245-8
11752306
Genes Dev. 1994 Jan;8(2):160-73
8299936
Nat Cell Biol. 2000 Feb;2(2):110-6
10655591
Curr Med Chem. 2001 Nov;8(13):1589-604
11562287
Genetics. 1998 Aug;149(4):1809-22
9691039
Trends Pharmacol Sci. 2008 May;29(5):250-7
18407359
J Biol Chem. 2008 Feb 15;283(7):3854-65
18083711
Curr Top Med Chem. 2007;7(1):63-82
17266596
Bioorg Med Chem Lett. 2006 Dec 15;16(24):6281-7
17000106
Biotechnol J. 2006 Dec;1(12):1405-18
17109493
Curr Pharm Des. 2000 Jan;6(1):59-98
10637372
Chem Biol. 2000 Apr;7(4):R85-94
10779412
Nat Struct Biol. 2002 Apr;9(4):268-72
11896401
Mol Biol Cell. 2002 Jun;13(6):2031-44
12058067
Curr Top Med Chem. 2008;8(16):1452-67
18991731
J Biol Chem. 2000 Oct 13;275(41):31755-62
10915787
J Med Chem. 2002 Jul 4;45(14):2994-3008
12086485
Curr Opin Immunol. 1993 Apr;5(2):282-6
8507407
Clin Cancer Res. 2008 Jan 15;14(2):342-6
18223206
Biochem Biophys Res Commun. 2005 Oct 14;336(1):357-63
16139248
EMBO J. 2001 Feb 1;20(3):466-79
11157753
Drug News Perspect. 2008 Jun;21(5):245-50
18596988
Adv Cancer Res. 1998;74:49-139
9561267
Chembiochem. 2005 Mar;6(3):481-90
15742384
EMBO J. 2002 Sep 16;21(18):4831-40
12234923
Biochemistry. 2007 Aug 14;46(32):9187-98
17658892
Curr Opin Struct Biol. 2001 Oct;11(5):560-6
11785756
J Med Chem. 2001 Dec 6;44(25):4313-24
11728179
Trends Biochem Sci. 1996 Oct;21(10):373-4
8918190
Biochemistry. 1996 Dec 3;35(48):15143-8
8952461
J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):235-49
11274893
Science. 1992 Aug 21;257(5073):1078-82
1509259
Biochem J. 2000 Oct 1;351(Pt 1):95-105
10998351
Methods Mol Biol. 2009;503:65-88
19151937
Biochim Biophys Acta. 2004 Mar 11;1697(1-2):243-57
15023365
Biochem Biophys Res Commun. 2007 Feb 16;353(3):633-7
17194451
Rheumatology (Oxford). 2008 Apr;47(4):409-14
18187523
Pharmacol Ther. 2002 Feb-Mar;93(2-3):193-202
12191611
Drugs R D. 2008;9(6):397-434
18989991
Mol Cell. 2004 Sep 10;15(5):661-75
15350212
Eur J Cancer. 2002 Sep;38 Suppl 5:S11-8
12528768
Nature. 1994 Feb 24;367(6465):704-11
8107865
Trends Biochem Sci. 2000 Sep;25(9):448-53
10973059
Oncogene. 2007 May 14;26(22):3100-12
17496909
Curr Pharm Des. 2002;8(25):2269-78
12369855
J Biol Chem. 2000 Aug 11;275(32):24613-21
10811804
Comb Chem High Throughput Screen. 2005 Mar;8(2):181-95
15777182
EMBO J. 1998 Mar 16;17(6):1740-9
9501095
Structure. 1998 Sep 15;6(9):1117-28
9753691
Blood. 2000 Sep 1;96(5):1655-69
10961860
J Chem Inf Comput Sci. 2001 Sep-Oct;41(5):1308-15
11604031
J Med Chem. 2005 Jul 14;48(14):4586-95
15999996
Nat Cell Biol. 2002 Aug;4(8):556-64
12134156
Cancer Res. 1989 Sep 1;49(17):4682-9
2547513
J Med Chem. 2004 Jul 1;47(14):3502-11
15214778
J Mol Biol. 1982 Oct 25;161(2):269-88
7154081
J Biol Chem. 1999 Jan 29;274(5):2893-8
9915826
J Biol Chem. 2001 Jul 20;276(29):27256-65
11371562
Cancer Res. 2004 Oct 1;64(19):7099-109
15466206
Cancer Res. 2002 Dec 1;62(23):6997-7000
12460918
Methods Enzymol. 2008;439:425-49
18374181
J Biol Chem. 2001 Jan 12;276(2):965-73
11029469
Angew Chem Int Ed Engl. 2002 Aug 2;41(15):2644-76
12203463
J Chem Inf Comput Sci. 2003 Jan-Feb;43(1):267-72
12546562